{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T02:04:11Z","timestamp":1784340251366,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01116-5","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T11:56:38Z","timestamp":1724327798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial"],"prefix":"10.1038","volume":"14","author":[{"given":"Gianluca","family":"Cavallaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pavoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Caterina","family":"Mic\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Busca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene Maria","family":"Cavattoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-0515","authenticated-orcid":false,"given":"Stella","family":"Santarone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Borghero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7840-4414","authenticated-orcid":false,"given":"Giuseppe","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1355-1587","authenticated-orcid":false,"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3277-6594","authenticated-orcid":false,"given":"Pellegrino","family":"Musto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Saporiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1035-4972","authenticated-orcid":false,"given":"Paolo","family":"Rivela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Terruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3638-0650","authenticated-orcid":false,"given":"Raffaella","family":"Cerretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Marotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Michele","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9186-1353","authenticated-orcid":false,"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Paola","family":"Iori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mordini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Oldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Di Grazia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bacigalupo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3739-7502","authenticated-orcid":false,"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"1116_CR1","doi-asserted-by":"publisher","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","volume":"26","author":"A D\u2019Souza","year":"2020","unstructured":"D\u2019Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177\u201382.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1116_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1182\/blood-2015-07-604546","volume":"127","author":"JJ Cornelissen","year":"2016","unstructured":"Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016;127:62\u201370.","journal-title":"Blood"},{"key":"1116_CR3","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1007\/s00277-021-04565-1","volume":"100","author":"T Heinicke","year":"2021","unstructured":"Heinicke T, Krahl R, Kahl C, Cross M, Scholl S, Wolf HH, et al. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials. Ann Hematol. 2021;100:2387\u201398.","journal-title":"Ann Hematol"},{"key":"1116_CR4","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"A Nagler","year":"2013","unstructured":"Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus cy as conditioning regimen\u2014a report from the acute leukemia working. J Clin Oncol. 2013;31:3549\u201356.","journal-title":"J Clin Oncol"},{"key":"1116_CR5","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","volume":"122","author":"EA Copelan","year":"2013","unstructured":"Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122:3863\u201370.","journal-title":"Blood"},{"key":"1116_CR6","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","volume":"35","author":"BL Scott","year":"2017","unstructured":"Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017;35:1154\u201361.","journal-title":"J Clin Oncol"},{"key":"1116_CR7","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","volume":"104","author":"M De Lima","year":"2004","unstructured":"De Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857\u201364.","journal-title":"Blood"},{"key":"1116_CR8","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","volume":"14","author":"BS Andersson","year":"2008","unstructured":"Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS. Biol Blood Marrow Transplant. 2008;14:672\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1116_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/sj.bmt.1705770","volume":"40","author":"YS Chae","year":"2007","unstructured":"Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant. 2007;40:541\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1116_CR10","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.bbmt.2008.06.009","volume":"14","author":"CN Bredeson","year":"2008","unstructured":"Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:993\u20131003.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1116_CR11","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A, Boschini C, Mic\u00f2 MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525\u201336.","journal-title":"Lancet Oncol"},{"key":"1116_CR12","doi-asserted-by":"crossref","unstructured":"Rizzo JD, Curtis RE, Sobocinski KA, Gilbert E, Landgren O, Travis LB, et al. Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009;113:1175\u201383.","DOI":"10.1182\/blood-2008-05-158782"},{"key":"1116_CR13","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2352-3026(18)30022-X","volume":"5","author":"F Fasslrinner","year":"2018","unstructured":"Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase. Lancet Haematol. 2018;5:e161\u20139.","journal-title":"Lancet Haematol"},{"key":"1116_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.hemonc.2017.05.009","volume":"10","author":"NS Majhail","year":"2017","unstructured":"Majhail NS. Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10:220\u20137.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"1116_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-8722-6-15","volume":"6","author":"H Liu","year":"2013","unstructured":"Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicen. J Hematol Oncol. 2013;6:1\u20139.","journal-title":"J Hematol Oncol"},{"key":"1116_CR16","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.20.02308","volume":"39","author":"C Craddock","year":"2021","unstructured":"Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39:768\u201378.","journal-title":"J Clin Oncol"},{"key":"1116_CR17","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Rem\u00e9nyi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3. Lancet Haematol. 2020;7:e28\u201339.","journal-title":"Lancet Haematol"},{"key":"1116_CR18","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41409-022-01830-3","volume":"57","author":"E Gavriilaki","year":"2022","unstructured":"Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, et al. Comparative study of treosulfan plus fludarabine (FT14) with busulfan plus fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia. Bone Marrow Transplant. 2022;57:1803\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"1116_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41409-022-01882-5","volume":"58","author":"R Swoboda","year":"2023","unstructured":"Swoboda R, Labopin M, Giebel S, Schroeder T, Kr\u00f6ger N, Arat M, et al. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party. Bone Marrow Transplant. 2023;58:282\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"1116_CR20","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1200\/JCO.23.00101","volume":"41","author":"Y Ling","year":"2023","unstructured":"Ling Y, Xuan L, Xu N, Huang F, Fan Z, Guo Z, et al. Busulfan plus fludarabine compared with busulfan plus cyclophosphamide for AML undergoing HLA-haploidentical hematopoietic cell transplantation: a multicenter randomized phase III trial. J Clin Oncol. 2023;41:4632\u201342.","journal-title":"J Clin Oncol"},{"key":"1116_CR21","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","volume":"29","author":"JR Wingard","year":"2011","unstructured":"Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230\u20139.","journal-title":"J Clin Oncol"},{"key":"1116_CR22","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1182\/blood-2010-07-294629","volume":"117","author":"NS Majhail","year":"2011","unstructured":"Majhail NS, Brazauskas R, Douglas Rizzo J, Sobecks RM, Wang Z, Horowitz MM, et al. Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011;117:316\u201322.","journal-title":"Blood"},{"key":"1116_CR23","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/j.bbmt.2014.07.009","volume":"20","author":"O Ringd\u00e9n","year":"2014","unstructured":"Ringd\u00e9n O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D, et al. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014;20:1777\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1116_CR24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/leu.2012.299","volume":"27","author":"A Shimoni","year":"2013","unstructured":"Shimoni A, Shem-Tov N, Chetrit A, Volchek Y, Tallis E, Avigdor A, et al. Secondary malignancies after allogeneic stem-cell transplantation in the era of reduced-intensity conditioning; the incidence is not reduced. Leukemia. 2013;27:829\u201335.","journal-title":"Leukemia"},{"key":"1116_CR25","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrclinonc.2012.150","volume":"9","author":"JJ Cornelissen","year":"2012","unstructured":"Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornh\u00e4user M, Juliusson G, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012;9:579\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"1116_CR26","doi-asserted-by":"publisher","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","volume":"27","author":"BL Scott","year":"2021","unstructured":"Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, et al. Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes\u2014long-term follow-up of the BMT CTN 0901 clinical trial: B. Scott et al. Transplant Cell Ther. 2021;27:483.e1\u2013e6.","journal-title":"Transplant Cell Ther"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01116-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01116-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01116-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:51:28Z","timestamp":1724388688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01116-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1116"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01116-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4595013\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}